In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

Pharmacogenetics

Volumn 11, Issue 9, 2001, Pages 781-791

  Lin, Y S ^a   Lockwood, G F ^a   Graham, M A ^a   Brian, W R ^a   Loi, C M ^a   Dobrinska, M R ^a   Shen, D D ^a   Watkins, P B ^a   Wilkinson, G R ^a   Kharasch, E D ^a   Thummel, K E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CYP3A; Drug interactions; Limited sampling; Midazolam; Phenotyping

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; RIFAMPICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; ENZYME INDUCTION; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AREA UNDER CURVE; ASIAN AMERICANS; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HALF-LIFE; HISPANIC AMERICANS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MIDAZOLAM; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDIES;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0035218021     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200112000-00006     Document Type: Article

References (33)

1. Cytochrome P450 3A4: Regulation and role in drug metabolism
2. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450
3. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons
4. CYP3A
5. In vitro and in vive drug interactions involving human CYP3A
6. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
7. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
8. Detection of a CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein?
9. Sequence diversity in CYP3A promoters and characterization of the genetic basis for polymorphic CYP3A5 expression
10. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method
11. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
12. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
13. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
14. Pharmacokinetics and bioavailability of midazolam in man
15. 14C-midazolam in humans following oral dosing
16. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
17. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
18. Perinatal expression and inducibility of human CYP3A7 in C57BL/6N transgenic mice
19. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
20. First-pass metabolism of midazolam by the human intestine
21. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: Evidence for specificity toward P-450 2E1
22. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions
23. The erythromycin breath test predicts the clearance of midazolam
24. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity
25. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects
26. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism
27. Maintenance-dose prediction based on a single determination of concentration: General applicability to two-compartment drugs with reference to lithium
28. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers
29. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe
30. Midazolam: A review of its pharmacological properties and therapeutic use
31. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
32. Humanized xenobiotic response in mice expressing nuclear receptor SXR
33. CYP3A activity in European-American and Japanese men using midazolam as an in vivo probe